ALLMedicine™ Cholangiocarcinoma Center

Mar 6th, 2021 - Immune regulation has an important role in cancer development, particularly in organs with continuous exposure to environmental pathogens, such as the liver and gastrointestinal tract. Chronic liver inflammation can lead to the development of hepa...

Mar 5th, 2021 - Transfusion-related acute lung injury (TRALI) is a transfusion complication often mediated by recipient exposure to plasma from donors with human leukocyte antigen (HLA) and human neutrophil antigen (HNA) antibodies. Recipient anti-donor HLA or HN...

Mar 4th, 2021 - Alpha-1 antitrypsin (AAT) deficiency, which is an under-recognised metabolic genetic disorder, is known to cause severe lung disease and liver cirrhosis in about 10%-15% of cases. Patients with AAT deficiency are at a higher risk for developing he...

Mar 3rd, 2021 - Liver resection (LR) is a major treatment modality in select patients with stage I-III Intrahepatic cholangiocarcinoma (ICC), yet many studies demonstrated low rates of resection. The aim of the present study is to evaluate whether increasing rese...

Mar 3rd, 2021 - Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated d...

Jul 15th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

Mar 6th, 2021 - Immune regulation has an important role in cancer development, particularly in organs with continuous exposure to environmental pathogens, such as the liver and gastrointestinal tract. Chronic liver inflammation can lead to the development of hepa...

Mar 5th, 2021 - Transfusion-related acute lung injury (TRALI) is a transfusion complication often mediated by recipient exposure to plasma from donors with human leukocyte antigen (HLA) and human neutrophil antigen (HNA) antibodies. Recipient anti-donor HLA or HN...

Mar 4th, 2021 - Alpha-1 antitrypsin (AAT) deficiency, which is an under-recognised metabolic genetic disorder, is known to cause severe lung disease and liver cirrhosis in about 10%-15% of cases. Patients with AAT deficiency are at a higher risk for developing he...

Mar 3rd, 2021 - Liver resection (LR) is a major treatment modality in select patients with stage I-III Intrahepatic cholangiocarcinoma (ICC), yet many studies demonstrated low rates of resection. The aim of the present study is to evaluate whether increasing rese...

Mar 3rd, 2021 - Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated d...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Feb 19th, 2020 - Figure 1. Common bile duct and pancreatic duct Perihilar tumors, also called Klatskin tumors, are the most common cholangiocarcinomas. They occur in the hilum region at the bifurcation of the right and left hepatic ducts. Intrahepatic tumors are t...

Feb 19th, 2020 - Even though the rates of resection with tumor-free margins have improved with more aggressive surgical approaches and improved radiologic techniques, recurrence rates remain high (49%-64%). These recurrences usually occur within 2-3 years post-res...